CG
SVA

Cutler Group’s Sinovac Biotech, Ltd SVA Stock Holding History

Cutler Group’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-2,800
Closed -$16K – 7788
2017
Q1 		$16K Hold
2,800
– – ﹤0.01% 3596
2016
Q4 		$16K Hold
2,800
– – ﹤0.01% 3735
2016
Q3 		$16K Sell
2,800
-100
-3% -$588 ﹤0.01% 3699
2016
Q2 		$17K Sell
2,900
-2,200
-43% -$13.5K ﹤0.01% 3568
2016
Q1 		$32K Buy
5,100
+5,000
+5,000% +$30K ﹤0.01% 2798
2015
Q4 		$0 Buy
+100
New +$538 ﹤0.01% 6454

Other funds holding SVA

SA
SAIF Advisors Admiralty, Hong Kong $438M AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GP
GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Cutler Group's SVA Position: Q2 2017 in Review

Cutler Group sold out of Sinovac Biotech, Ltd (SVA) in Q2 2017, closing a stake of 2,800 shares — an estimated $16K sold.

Cutler Group first reported a position in SVA in Q4 2015 and held it in 6 quarters. The position peaked at $32K in Q1 2016. 37 funds tracked by Wall St. Rank hold SVA as of Q2 2017.

  • Cutler Group reported no remaining Sinovac Biotech, Ltd position as of Q2 2017 after selling out during the quarter.
  • Cutler Group sold 2,800 Sinovac Biotech, Ltd shares in Q2 2017, an estimated $16K.
  • Cutler Group first reported a position in Sinovac Biotech, Ltd in Q4 2015 and held it in 6 quarters.
  • Cutler Group's Sinovac Biotech, Ltd position peaked at $32K in Q1 2016.
  • 37 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q2 2017.

Based on Cutler Group's 13F filing for Q2 2017, filed 11 Jul 2017.